Old Web
English
Sign In
Acemap
>
Paper
>
PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE
PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE
2019
S Teitsson
B. Bregman
François-Emery Cotté
M. Augusto
A. Amadi
A. Moshyk
S Roze
Anne-Françoise Gaudin
Keywords:
Adjuvant
Melanoma
Medicine
Nivolumab
Cost–utility analysis
Intensive care medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]